New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
08:13 EDTINFIInfinity sees reporting data from both wholly owned clinical programs in 1H13
In the first half of 2013, Infinity expects to report data from both of its wholly owned clinical programs, phosphoinositide-3-kinase and heat shock protein 90, that will inform potential paths to registration. Each program targets areas of unmet patient need such as advanced hematologic malignancies, inflammatory diseases and non-small cell lung cancer. Infinity also announced its second potent, oral PI3K-delta,gamma inhibitor, IPI-443. Nonclinical studies of IPI-443 are now under way, which are designed to enable the initiation of Phase 1 clinical development. Infinity is developing a portfolio of PI3K inhibitors which includes IPI-145 and IPI-443, potent, oral inhibitors of PI3K-delta and PI3K-gamma, as well as retaspimycin hydrochloride, a potent and selective Hsp90 inhibitor.
News For INFI From The Last 14 Days
Check below for free stories on INFI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 6, 2014
10:00 EDTINFIOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:51 EDTINFIInfinity Pharma new royalty option facilitates partnership, says RBC Capital
Subscribe for More Information
08:21 EDTINFIInfinity Pharmaceuticals upgraded to Outperform at William Blair
William Blair upgraded Infinity Pharmaceuticals to Outperform from Market Perform following the company's Q2 results but lowered its price target for shares to $14.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use